This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
https://awmsg.nhs.wales/
.
Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
sofosbuvir/velpatasvir (Epclusa®)
Reference No. 2417
Publication date:
21/11/2016
Appraisal information
sofosbuvir/velpatasvir (Epclusa®) 400 mg/100 mg film-coated tablet
Company:
Gilead Sciences Ltd
BNF category:
Infections
NMG meeting date:
05/10/2016
AWMSG meeting date:
09/11/2016
Submission Type:
Directed
Status:
Superseded
Advice No:
3116
Ratification by Welsh Government:
18/11/2016
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA430) NICE GUIDANCE ISSUED JANUARY 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
sofosbuvir-velpatasvir (Epclusa) 2417 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
sofosbuvir-velpatasvir (Epclusa) 2417 ASAR
Clinical Expert (CE) Summary
Download
sofosbuvir-velpatasvir (Epclusa) 2417 CE summary
